Clinical Trials Logo

Clinical Trial Summary

We propose a use of a unique facility, the databank at the CNDV, to examine the impact of switching subjects to asenapine in an open-label naturalistic setting. This offers the following advantages: i) providing data on a particularly important population, i.e., subjects who are at the inception of treatment for a psychotic disorder and who are likely to remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical setting, with a clinical team dedicated to provide innovative interventions; iii) its naturalistic design, that will allow to obtain data that will be applicable to "real-life" clinical settings; indeed, subjects who will be switched to asenapine within the current project are those we would switch to this drug in our daily practice.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01968161
Study type Interventional
Source Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Contact
Status Not yet recruiting
Phase Phase 4
Start date October 2013
Completion date March 2014

See also
  Status Clinical Trial Phase
Completed NCT01196858 - Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland N/A
Completed NCT00136760 - Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia Phase 2
Completed NCT03309475 - Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind) N/A
Completed NCT00135772 - Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2 N/A
Completed NCT02308462 - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents N/A
Completed NCT03133143 - Video Games Among People With Schizophrenia N/A
Completed NCT00309452 - Specialized Treatment Early in Psychosis (STEP) N/A
Not yet recruiting NCT02240173 - Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia Phase 1/Phase 2
Completed NCT00218218 - Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia Phase 2
Completed NCT02321943 - Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study N/A
Completed NCT02928965 - The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms Phase 2
Completed NCT02307396 - Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Phase 4
Terminated NCT00748566 - One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome Phase 4
Recruiting NCT00791882 - Social Skills Training in Refractory Schizophrenia N/A
Completed NCT00363181 - Side Effects of Antipsychotic Medications
Completed NCT00137189 - Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation N/A